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Abstract
Background: Indocyanine green (ICG) excretory defect is a dye excretory disorder, and it is characterized by the
selective impairment of plasma ICG clearance with normal liver histology. The pathophysiology involves selective
loss of active transporters for ICG in the hepatic cell membrane. Several cases of hepatectomy in patients with ICG
excretory defect have been reported, but the expression of hepatic transporters involved in ICG excretory defect
has not been examined in these cases.
Case presentation: An 81-year-old man who was hepatitis B and C virus negative was admitted to our hospital
with a diagnosis of HCC. Abdominal computed tomography revealed an 8-cm-diameter tumor in hepatic segments
4 and 8. The retention rate of ICG at 15 min (ICGR15), which has been used to evaluate hepatic functional reserve,
was markedly elevated (79.1 %), whereas other liver function test results, were normal. Therefore, we diagnosed the
patient with HCC with an ICG excretory defect, and considered major hepatectomy. Central bisectionectomy was
performed, and the postoperative course was uneventful. Microscopic examination of the resected specimen
showed moderately differentiated HCC. Immunohistochemical staining and polymerase chain reaction analysis
of a non-neoplastic site of the resected specimen showed very few expression of the organic anion-transporting
polypeptide 1B3 (OATP1B3), which is usually expressed on the basolateral membrane of human hepatocytes and
mediates the uptake of ICG.
Conclusions: In this case, we present a case of hepatectomy for HCC in a patient with ICG excretory defect, which
may be attributable to a congenital disorder of OATP1B3 expression; however, an ICG excretory defect did not
seem to have any effect on the short-term prognosis after hepatectomy.
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Background
Hepatectomy is performed within the limits of hepatic
functional reserve. For many years, the indocyanine
green (ICG) test has been used to evaluate hepatic func-
tional reserve; however, it is difficult to accurately assess
hepatic functional reserve in the presence of an ICG
excretory defect [1]. We encountered a rare case of
hepatocellular carcinoma (HCC) with an ICG excretory
defect treated with major hepatectomy on the basis of a
normal hepatic uptake ratio on 99mTc-diethylene tria-
mine pentaacetic acid-galactosyl human serum albumin
(GSA) liver scintigraphy and otherwise normal liver
function test results. ICG excretory defect was first re-
ported by Namihisa et al. in 1974, as a new type of dye
excretory disorder [2]. It is characterized by the selective
impairment of plasma ICG clearance with normal liver
histology. The pathophysiology involves selective loss of
active transporters for ICG in the hepatic cell membrane
[3]. Recently, it has been reported that organic anion
transporting polypeptides (OATPs; encoded by SLCOs)
and Na+-taurocholate cotransporting polypeptides (NTCPs;
encoded by SLC10A1), which are present in the basolat-
eral membrane of human hepatocytes, are important
transporters for the uptake of substances and xenobiotics,
and are positively correlated with the transporters for ICG
[4]. Here, we report the association between ICG excre-
tory defect and the expression of OATPs and NTCPs. Al-
though there are several previous reports of hepatectomy
in patients with an ICG excretory defect, we believe that
this is the first case of HCC with an excretory defect
in which the expression of hepatic transporters was
examined.
Case presentation
An 81-year-old man who was hepatitis B and hepatitis C
virus negative was admitted to our hospital with a diag-
nosis of HCC. He underwent preoperative examination
for hepatectomy, including the ICG test. Physical exam-
ination indicated no tenderness in the abdomen or palp-
able mass. Blood tests showed slightly elevated levels of
aspartate transaminase (65 IU/L; normal, <40 IU/L) and
alanine transaminase (77 IU/L; normal, <40 IU/L),
and markedly elevated levels of serum α-fetoprotein
(125.5 ng/mL; normal, <6.5 ng/mL) and protein in-
duced by vitamin K absence or antagonist II (5266 AU/
mL; normal, <40 AU/mL). We performed ICG tests three
times before hepatectomy; retention rates of ICG at
15 min (ICGR15) were markedly high, at 69.2, 58.5, and
79.1 %. All other laboratory data, including prothrombin
activity (106 %; normal, >80 %), albumin level (3.9 g/dl;
normal, >3.8 g/dl), and total bilirubin level (1.1 mg/dl;
normal, <1.2 mg/dl), were normal, and the Child-Pugh
score was A. Computed tomography (CT) revealed an
8-cm-diameter tumor in hepatic segments 4 and 8.
Additionally, the tumor had heterogeneously high at-
tenuation on CT during hepatic arteriography, and low
attenuation on CT arterial portography. Angiography
showed no mesosystemic or intrahepatic shunts. GSA
liver scintigraphy showed reduced accumulation of GSA
in segments 4 and 8 (Fig. 1a); the receptor index and index
of blood clearance were normal, 0.91 (normal, >0.9)
and 0.60 (normal, <0.61), respectively. In gadolinium-
ethoxybenzyl-diethylene triamine pentaacetic acid
(Gd-EOB-DTPA)-enhanced magnetic resonance imaging
(MRI), the neoplastic site showed low signal intensity
(Fig. 1b–e), and the non-neoplastic site was slightly en-
hanced on the hepatobiliary phase with poor contrast en-
hancement to spleen or vessels. The liver spleen contrast
ratio of signal intensity was 1.25, which was rather low
value compared to the previous report (Fig. 1f) [5]. CT
volumetry estimated that the central bisection, which was
the area of the expected resection, occupied 40 % of the
total parenchymal volume. Based on the hepatic func-
tional reserve of this patient, as indicated by GSA liver
scintigraphy and liver function tests, central bisectionect-
omy was considered feasible. We decided to perform
hepatectomy.
Intraoperatively, the surface of the liver was smooth
and the edge was sharp. There was no ascites, spleno-
megaly, mesosystemic shunt, or evidence of chronic
hepatitis. Therefore, we performed central bisectionect-
omy without complications (Fig. 2a, b). The patient’s
postoperative course was good, and he was discharged
3 weeks after hepatectomy. The ICGR15 3 months after
hepatectomy was still high at 62.9 %, although other
blood test results, including levels of tumor markers,
were normal. Pathological examination of the resected
specimen revealed moderately differentiated HCC with
mild chronic inflammation in the adjacent liver tissue
(Fig. 2c, d). Immunohistochemical staining and reverse
transcription polymerase chain reaction (RT-PCR) ana-
lysis of neoplastic and non-neoplastic sites of the
resected specimens were examined in the same way as
previous report [6]. Immunostaining was performed by
using mouse monoclonal antibodies to OATP1B3
(NB100-74482, Novus Biologicals), OATP1B1 (ab15442,
Abcam), and MRP2 (ab3373, Abcam). RT-PCR was done
with following TaqMan® Gene Expression Assays ob-
tained from Applied Biosystems (Warrington, England):
OATP1B3 (encoded by SLCO1B3): Hs00251986_m1,
OATP1B1 (encoded by SLCO1B1): Hs00272374_m1,
NTCP (encoded by SLC10A1): Hs00161820_m1, MRP2
(encoded by ABCC2): Hs00166123_m1, MRP3 (encoded
by ABCC3): Hs00978473_m1. Theses examinations re-
vealed no or very few expressions of OATP1B3, which is
localized to the basolateral membrane of human hepato-
cytes and mediates the uptake of agents such as ICG
and Gd-EOB-DTPA (Fig. 3a–d and Fig. 4a). Expression
Imada et al. Surgical Case Reports  (2016) 2:89 Page 2 of 6
Fig. 2 Gross appearance of the resected specimen (a, b). Pathological examination of the resected specimen showed moderately differentiated
HCC and mild inflammation in neoplastic and non-neoplastic site (c, d)
Fig. 1 99mTc-DTPA-galactosyl human serum albumin (GSA) liver scintigraphy showed normal accumulation of GSA in non-neoplastic lesion (a).
Each gadolinium-ethoxybenzyl-diethylene triamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) showed
pre-contrast T1-weighted image (b), arterial dominant phase (c), portaldominant phase (d), transitional phase (e), and hepatobiliary phase (f).
Hepatobiliary phase showed slight enhance with poor contrast enhancement to spleen or vessels in non-neoplastic site
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of OATP1B1, another hepatic uptake transporter of the
OATP family, in non-neoplastic and neoplastic sites was
comparable with that in normal liver tissue on RT-PCR
(Fig. 4b), but immunohistochemical staining indicated
lower OATP1B1 expression than control (Fig. 3e–h).
The non-neoplastic site’s expressions of Na+-taurochol-
ate cotransporting polypeptide, a transporter that medi-
ates uptake from the blood into hepatocyte, and
multidrug resistance-associated protein 2 and 3 (MRP2
and MRP3), which mediate efflux from the hepatocyte
into the bile and blood, were comparable with normal
liver tissue (Fig. 3i–l and Fig. 4c–e).
Discussion
Hepatectomy is the optimal curative treatment in pa-
tients with HCC. However, hepatectomy is associated
with significant morbidity and mortality, especially in
patients with underlying chronic liver disease [7]. ICG is
a tricarbocyanine dye that was first introduced to meas-
ure blood flow, and later recognized as a useful com-
pound for liver function testing [4]. Several studies have
found the ICG clearance test to be the best test for
selecting patients for hepatectomy [8]. Some investiga-
tors have used the ICG clearance test alone to exclude
patients from hepatic resection if retention rates were
not satisfactory [9], while others use the ICG retention
rate to decide on the resection volume of the liver [10].
The ICG test is therefore well-established as a discri-
minating predictive test for the evaluation of hepatic
functional reserve. However, in patients with an ICG
excretory defect, the results of ICG tests become un-
reliable. An ICG excretory defect is indicated by a
discrepancy between the ICG test findings and other
conventional liver functional test results, and is character-
ized by selective impairment of plasma ICG clearance with
normal liver histology. The pathophysiology involves the
selective loss of active transporters for ICG in the hepatic
cell membrane. As a result, ICG uptake into hepatocytes
occurs by passive diffusion. The limited capacity of the
intrahepatic transport of ICG may be an accessory factor
in ICG excretory defect. With regard to hepatic trans-
porters, de Graaf et al. reported that the transporter speci-
ficity of 99mTc-mebrofenin and ICG partially overlap, as
both compounds are transported by the hepatic uptake
transporter OATP1B3. Furthermore, they reported that
99mTc-mebrofenin was also taken up by OATP1B1,
whereas ICG was additionally transported by NTCP [4].
Kitao et al. reported that the expression of both OATP1B3









































Fig. 4 Reverse transcription polymerase chain reaction analysis of
liver transporters in the resected specimens from our case and
control cases (a–e) (normalization to β-actin expression)
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with the signal intensity of HCC in the hepatobiliary phase
of Gd-EOB-DTPA-enhanced MRI [6]. In addition, they re-
ported that decreased OATP1B3 expression during multi-
step hepatocarcinogenesis resulted in the decrease in
enhancement ratio on Gd-EOB-DTPA-enhanced MRI
[11]. These findings suggested that hepatic transporters
for ICG, GSA, and Gd-EOB-DTPA are specific, but par-
tially overlap.
In the present case, immunohistochemical staining
and RT-PCR analysis of non-neoplastic and neoplastic
sites revealed very few expression of the hepatic up-
take transporter OATP1B3. It is possible that the de-
viation of the ICG test results from other liver function
test results is attributable to a congenital disorder of
OATP1B3.
Rotor syndrome (RS) should be considered in the dif-
ferential diagnosis of diseases associated with high reten-
tion rates of ICG. Van de Steeg et al. reported that
complete OATP1B1 and OATP1B3 deficiency caused
human RS by interrupting conjugated bilirubin reuptake
into the hepatocyte [12]. They analyzed the genome
sequences of 11 RS index subjects from eight differ-
ent families, and reported pathogenic mutations af-
fecting both SLCO1B3 and SLCO1B1. These mutations
resulted in disruption or annihilation of proper pro-
tein expression and function in each subject. We
could not analyze genome sequence of our patient,
although a pathogenic mutation of SLCO1B3 might
disrupt OATP1B3 protein expression, resulting in the
deviation of the ICG test results from other liver function
test results.
Several cases of hepatectomy in patients with an ICG
excretory defect have been reported [1, 3, 13, 14], and
hepatectomy could be performed safely within the limits
of hepatic functional reserve. It is certain that ICG
excretory defect itself does not affect hepatic func-
tional reserve from these results, but human
OATP1B1 and OATP1B3 mediate the uptake of many
drugs by the liver, and even polymorphisms of
OATP1B1 and OATP1B3 that are associated with re-
duced activity can result in life-threatening drug tox-
icities [12]. Takane et al. reported that a specified
genotype of uridine diphosphate glucuronosyltransfer-
ase 1A1 and SLCO1B1 caused life-threatening toxicity
after irinotecan-based chemotherapy [15]. Patients
who are candidates for surgical treatment will poten-
tially receive neoadjuvant or adjuvant chemotherapy
in the perioperative period. Although the patient in
the present case did not develop severe liver dys-
function after hepatectomy, we have to consider the
possibility of impaired expression of hepatocyte trans-
porters, and exercise caution when using therapeutic
drugs for patients with an ICG excretory defect
(Fig. 5).
Conclusions
In this case, we present a case of hepatectomy for HCC
in a patient with ICG excretory defect, which may be
attributable to a congenital disorder of OATP1B3 ex-
pression; however, an ICG excretory defect did not seem
to have any effect on the short-term prognosis after
hepatectomy.
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